Adults (Male and Female Subjects) With Tobacco Dependence
Conditions
Keywords
Tobacco, addiction, transcranial non invasive direct brain stimulation, adults
Brief summary
In summary, there are currently many therapeutic tools for achieving some degree of control or even cessation of tobacco addictive use. No single therapy seems to have proven itself sufficiently effective to be the preferred treatment axis in the management of this addiction. We can also point out that so far the main treatments aimed at reducing or controlling the craving phenomenon are of a pharmacological nature, thus exposing the participants to the side effects inherent to this type of treatment. In this perspective, the establishment of non invasive brain stimulation (TdCS), acting in a targeted manner on craving and whose effects would be mild and transient, appears quite justified, especially in addition to psychotherapy. In the context of the management of addictive pathologies, the choice of smoking dependence seems relevant to us insofar as this addiction represents a major public health problem.
Interventions
OTHERTranscranial Direct Current Stimulation
tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
Sponsors
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Men and women over the age of 18 * Nicotine dependent subjects according to the Fagerström test (score ≥5) * Subjects consuming daily tobacco. * Subjects understanding and reading French and able to express themselves in this language. * Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study * Affiliation to the French social security scheme or beneficiary of such a scheme. * No other method to decrease or stop smoking at the same time as the study.
Exclusion criteria
* Guardianship * Pregnant or lactating woman * Patient under AME * Subject being in the exclusion period of another study or provided for by the National Volunteer File. * Subjects with intracranial hypertension * Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator. * Treatment with buproprion or varenicline in progress * Episode or family history of epilepsy, convulsion. * Disease causing damage to the brain (aneurysm, tumor, ...). * Cochlear or ocular implant. * Stimulator or cardiac defibrillator. * Presence of metal in the skull (clip on aneurysm, prosthesis, ...). * Eczema on the scalp.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fagerström score (3 is the highest score and O the lowest one for item 1. A score of 1 or 2 means low dependence (for item 1 only as well as if you use the total score) | 15 days | average difference in Fagerström score 1 scores that assess craving for tobacco between pre-treatment assessment (J0) and short-term post-treatment evaluations (J15). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tobacco consumption | 15 days | Evaluation of changes in tobacco consumption and smoking craving intensity and tolerance of tDCS |
Countries
France
Contacts
Primary ContactFlorence THIBAUT, PHD
Backup ContactMarie BENHAMMANI-GODARD
Outcome results
None listed